Vaccines Europe pipeline review

Dashboard

Vaccines Europe conducted a pipeline review of its 15 member companies, including information up to July 2022.

The review shows a promising vaccines pipeline aimed at tackling the challenges of today and tomorrow, such as the burden of respiratory tract infections, AMR, the ageing of the population, climate change and zoonotic infections, through leveraging a broad array of technology platforms.

Download pipeline review

Overview data

100

vaccine candidates in Vaccines Europe members’ pipeline, of which 92 are prophylactic vaccines and 8 are therapeutic vaccines.

46%

of the vaccine candidates aim to address disease areas for which no vaccine has been registered yet.

54%

of the vaccine candidates aim to further develop existing vaccines or find a new approach to address a disease.

22

of the vaccine candidates are for routine immunisation.

5

vaccine candidates aim to treat different types of cancer.

11

vaccine candidates are targeting antibiotic-resistant pathogens.

Over 80%

of the vaccine candidates are tested in adults and older adults.

10

different technology platforms are being used by Vaccines Europe members in their pipelines.

Over 50%

of vaccine candidates aim to tackle respiratory-transmitted diseases.

Almost 10%

of vaccine candidates are therapeutic.

Over 10%

of vaccine candidates are for travel.

50%

of vaccine candidates are focused on preventing zoonotic diseases.

Explore the latest vaccines in development

Search by

All Disease Areas
Technology Platforms
Development Phases
Trial Population

OR SEARCH BY REPORT SECTIONS

Routine vaccines
across the lifespan
Travel
vaccines
Antimicrobal
resistance
Therapeutic
vaccines
Climate
change
Zoonoses
and pandemic
preparedness

Charts

By the end of July 2022, there were 100 vaccine candidates in the Vaccines Europe members’ pipeline. Most of these target infectious diseases caused by viruses. The majority of vaccine candidates target the adult population, especially for those at higher risk for serious disease infection. Meanwhile, almost half of the vaccine candidates target diseases for which there are no registered vaccines yet.

How can Europe take full advantage of this promising vaccines pipeline?

1
Ensure sustainable immunisation financing in EU Member States
2
Enhance vaccine market access pathways in Europe 
3
Embed adult vaccination in national immunisation programmes to improve country readiness 

EU Vaccines Pipeline Review

Download our pipeline review
PRIVACY POLICY
Members area
PRIVACY POLICY
© Vaccines Europe - a specialised group
of EFPIA - all rights reserved

CHOOSE THE DISEASE OR PATHOGEN

Chikungunya Virus

Clostridioides difficile infection (CDI)

Coronaviruses

Cytomegalovirus

Dengue fever

Ebola

Epstein-Barr virus (EBV) infection

Extraintestinal pathogenic Escherichia coli (ExPEC)

Glioblastoma

Group B Streptococcus Infection

Hepatitis B​

Herpes simplex virus

Human immunodeficiency virus (HIV)

Human metapneumovirus and parainfluenza virus 3 (hMPV/PIV3)

Influenza

Klebsiella pneumoniae

Lung/Colorectal Pancreatic cancer

Lyme disease (Borreliosis)

Malaria

Meningococcal disease

Nipah virus (NiV)

Pneumococcal disease

Rabies

Respiratory Syncytial Virus (RSV)​

Shigellosis

Skin & soft-tissue Infections caused by Staphylococcus aureus

Skin cancer

Solid tumour

Varicella

Yellow fever

Zika

CHOOSE A DEVELOPMENT PHASE

Phase I

Phase II

Phase III

Under Regulatory Review

CHOOSE A TECHNOLOGY PLATFORM

Glycoconjugate vaccine

Live-attenuated virus​

Multiple platforms

Protein nanoparticles

Protein subunit​

mRNA

Toxoid vaccine

Viral vector

Virus-like particle​

Whole-inactivated virus

CHOOSE A TRIAL population

Paediatric

Infants and children
under 18 years old

Adults

18-60 years old

Maternal Immunisation

Older Adults

Over 60 years old